EYESEE

Development of new gene therapy approaches for the treatment of ocular neovascularization

 Coordinatore UNIVERSIDADE DO ALGARVE 

 Organization address address: CAMPUS DE PENHA
city: FARO
postcode: 8005 139

contact info
Titolo: Dr.
Nome: António
Cognome: Cabecinha
Email: send email
Telefono: -800038
Fax: -810

 Nazionalità Coordinatore Portugal [PT]
 Totale costo 100˙000 €
 EC contributo 100˙000 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2009-RG
 Funding Scheme MC-IRG
 Anno di inizio 2009
 Periodo (anno-mese-giorno) 2009-11-01   -   2013-10-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    UNIVERSIDADE DO ALGARVE

 Organization address address: CAMPUS DE PENHA
city: FARO
postcode: 8005 139

contact info
Titolo: Dr.
Nome: António
Cognome: Cabecinha
Email: send email
Telefono: -800038
Fax: -810

PT (FARO) coordinator 100˙000.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

efficiency    transfer    therapeutic    diseases    vision    blindness    therapy    vectors    nv    impact    ocular    anti    strategies    disease    angiogenic    therapies    ones    progression    retinopathy    viral    gene   

 Obiettivo del progetto (Objective)

'Ocular neovascularization (NV) is the pathological feature common to Retinopathy of Prematurity, Diabetic Retinopathy, and Age-related Macular Degeneration. Collectively, these diseases are the leading cause of blindness in developed countries, and even more relevant due to the increased life expectancy. Current therapies can delay the progression of the disease, but do not restore the vision already lost. Therefore, there is a need for new, more efficient anti-angiogenic therapies. Gene therapy has been successfully used in several ocular disease paradigms. Most gene therapy strategies have used viral vectors due to their gene transfer efficiency. Nevertheless, viral vectors have several limitations, the most important ones the risk of random integration into the genome and potential severe immune response. Non-viral vectors have the potential to overcome the drawbacks associated with viral vectors but, to date, non-viral vectors still lag behind viral ones in gene transfer efficiency. This proposal aims to address both the need for new therapeutic strategies to treat ocular NV and development of new non-viral vectors optimized for ocular gene therapy. This dual approach would be feasible due to the multidisciplinary background of the Coordinator of this proposal in gene therapy, biology and and materials science. This project will study the potential of combining the inhibition of angiogenic factors and the expression of anti-angiogenic factors, delivered by the developed non-viral vectors. The outcome of this project would be two-fold: 1) non-viral vectors with an efficiency comparable to viral ones and 2) new therapeutic strategies to prevent loss of vision caused by the progression of ocular NV. This can significantly contribute to European excellence by decreasing the knowledge gap and generate added value products that can simultaneously have an economic impact but mostly have a social impact, specially in those ailing from diseases causing blindness'

Altri progetti dello stesso programma (FP7-PEOPLE)

SIGMA1R (2014)

Structural Basis of Sigma-1 Receptor Ligand Interactions

Read More  

IN-SMC (2010)

SMOOTH MUSCLE CELL TRANSCRIPTOMICS AND INFECTIOUS AGENTS

Read More  

CELLSEC (2008)

Studying Plant Cell Secretion and Membrane Trafficking

Read More